GlaxoSmithKline's (GSK) Buy Rating Reiterated at Liberum Capital
's stock had its "buy" rating reaffirmed by investment analysts at Liberum Capital in a research report issued on Thursday, November 9th. They currently have a GBX 1,760 price objective on the stock.
from Biotech News
0 Comments